Low-dose X-ray therapy for COVID-19: lessons from the past

Nasir, Awais; Agrawal, Deepsha; Pathak, Jayashree; Theodoulou, Iakovos

doi:10.1259/bjr.20200581

Cited by 3 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LDRT induces an anti-inflammatory phenotype that can potentially give therapeutic benefits against Covid-19-related complications [ 143 , 148 , 158 , 162 , 163 , 175 ].…”

Section: Resultsmentioning

confidence: 99%

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Piras¹,

Venuti

D’Aviero³

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

Introduction Following the Covid-19 pandemic spread, changes in clinical practice were necessary to limit the pandemic diffusion. Also, oncological practice has undergone changes with radiotherapy (RT) treatments playing a key role. Although several experiences have been published, the aim of this review is to summarize the current evidence after 2 years of pandemic to provide useful conclusions for clinicians. Methods A Pubmed/MEDLINE and Embase systematic review was conducted. The search strategy was “Covid AND Radiotherapy” and only original articles in the English language were considered. Results A total of 2.733 papers were obtained using the mentioned search strategy. After the complete selection process, a total of 281 papers were considered eligible for the analysis of the results. Discussion RT has played a key role in Covid-19 pandemic as it has proved more resilient than surgery and chemotherapy. The impact of the accelerated use of hypofractionated RT and telemedicine will make these strategies central also in the post-pandemic period.

show abstract

“…LDRT induces an anti-inflammatory phenotype that can potentially give therapeutic benefits against Covid-19-related complications [ 143 , 148 , 158 , 162 , 163 , 175 ].…”

Section: Resultsmentioning

confidence: 99%

Covid-19 and radiotherapy: a systematic review after 2 years of pandemic

Piras¹,

Venuti

D’Aviero³

et al. 2022

Clin Transl Imaging

View full text Add to dashboard Cite

show abstract

“…Given the urgency of the COVID-19 pandemic and the understanding of the role CRS play in the pathophysiology of the virus, LDRT was investigated as a potential therapy approach [12][13][14][15] .…”

Section: Low-dose Radiotherapy For Covid-19 Pneumoniamentioning

confidence: 99%

The Influence of Low-Dose Radiotherapy on Paraoxonase-1 and Inflammatory Biomarkers in COVID-19 Pneumonia Patients

Royo,

Árquez,

Acosta

et al. 2024

MRAJ

View full text Add to dashboard Cite

The COVID-19 pandemic will be remembered for its significant health and economic impact worldwide. Severe pneumonia could often progress to acute respiratory distress syndrome (ARDS), this being a critical complication characterised by an exaggerated inflammatory response, known as cytokine-release syndrome (CRS). Amid debates regarding the efficacy of conventional treatments, low-dose Radiotherapy (LDRT) has emerged as a potential therapy due to its anti-inflammatory effects. LDRT modulates immune responses by polarizing macrophages towards an anti-inflammatory phenotype and reducing oxidative stress. While studies investigating LDRT for COVID-19 pneumonia have shown promising results, conflicting data has been published and challenges persist in patient selection and treatment timing. Biomarkers such as paraoxonase-1 activity hold promise for predicting treatment outcomes. LDRT presents an alternative approach to modulating the immune response in COVID-19 pneumonia, offering hope for improved clinical outcomes. Further research is warranted to validate its efficacy and elucidate underlying mechanisms. This article provides summary of the radioimmunological mechanisms and the results of biomarkers research in this context.

show abstract